BTA798 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Rhinovirus

Conditions

Rhinovirus

Trial Timeline

Aug 1, 2010 → Mar 1, 2012

NCT ID

NCT01175226

About BTA798 + Placebo

BTA798 + Placebo is a phase 2 stage product being developed by Vaxart for Rhinovirus. The current trial status is completed. This product is registered under clinical trial identifier NCT01175226. Target conditions include Rhinovirus.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01175226	Phase 2	Completed	Aug 1, 2010	Mar 1, 2012	Rhinovirus

Competing Products

1 competing product in Rhinovirus

See all competitors

Product	Company	Stage	Hype Score
Vapendavir + Placebo Oral Tablet	Vaxart	Phase 2	44

Other Products from Vaxart

Vapendavir + Vapendavir + PlaceboPhase 2

VXA-A1.1 + Fluzone®Phase 2

Vapendavir + Placebo Oral TabletPhase 2

VXA-CoV2-1.1-SPhase 2

40 mg Laninamivir Octanoate + 80 mg Laninamivir Octanoate + PlaceboPhase 2